Literature DB >> 21119604

MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro.

Z Jin1, F M Selaru, Y Cheng, T Kan, R Agarwal, Y Mori, A V Olaru, J Yang, S David, J P Hamilton, J M Abraham, J Harmon, M Duncan, E A Montgomery, S J Meltzer.   

Abstract

The dismal outcome of gastric cancer patients highlights the need for diagnostic biomarkers and effective therapeutic targets, such as microRNAs. We sought to discover microRNAs involved in gastric cancer, and to elucidate their downstream target mechanisms. Both cultured gastric epithelial cells (HFE145 and NCI-N87) and primary human gastric tissues (31 non-neoplastic stomach (NS) and 25 gastric carcinomas (GC)) were studied. MicroRNA microarrays and quantitative RT-PCR were applied to discover and verify differentially expressed microRNAs. in vitro cell migration and invasion, cell proliferation, cell cycle and apoptosis assays were executed to elucidate biological effects of microRNA-192 and -215. Western blotting and luciferase assays were performed to confirm direct messenger RNA targeting by microRNA-192 and -215. MicroRNA microarray analyses revealed that 25 and 20 microRNAs were upregulated and downregulated in GC vs NS, respectively. Expression levels of both microRNA-192 and -215 were significantly higher in GC than in NS (P<0.05). Luciferase assays suggested that microRNA-215 inhibits activated leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level. In addition, expression levels of ALCAM were significantly lower in GC than in NS. Mimics and inhibitors, respectively, of microRNA-192 or -215 exerted no effect on cell cycle or apoptosis in the immortalized normal gastric cell line HFE145 or the gastric cancer cell line NCI-N87. However, mimics of microRNA-192 or -215 significantly increased growth rates in HFE145 cells, whereas inhibitors of microRNA-192 or -215 caused significant decreases in growth rates in NCI-N87 cells. ALCAM knockdown by an ALCAM-specific siRNA significantly increased cell growth in HFE145 cells. Both transfection of mimics of microRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly increased the migration of HFE145 cells. In conclusion, in gastric cancer, both microRNA-192 and -215 are overexpressed in vivo and exert cell growth and migration-promoting effects in vitro, thus representing potential microRNAs with a role in cancer in the human stomach.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21119604      PMCID: PMC4586057          DOI: 10.1038/onc.2010.534

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR.

Authors:  J Robin Lytle; Therese A Yario; Joan A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

2.  Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.

Authors:  Agnieszka Jezierska; Wojciech P Olszewski; Jerzy Pietruszkiewicz; Włodzimierz Olszewski; Wojciech Matysiak; Tomasz Motyl
Journal:  Med Sci Monit       Date:  2006-06-28

3.  Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines.

Authors:  J H Kim; T Takahashi; I Chiba; J G Park; M J Birrer; J K Roh; H De Lee; J P Kim; J D Minna; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

Review 4.  Chromosomal imbalances in gastric cancer. Correlation with histologic subtypes and tumor progression.

Authors:  T Noguchi; H C Wirtz; S Michaelis; H E Gabbert; W Mueller
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

5.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

6.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.

Authors:  Sara A Georges; Matthew C Biery; Soo-Yeon Kim; Janell M Schelter; Jane Guo; Aaron N Chang; Aimee L Jackson; Michael O Carleton; Peter S Linsley; Michele A Cleary; B Nelson Chau
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation.

Authors:  Ulf Andersson Ørom; Finn Cilius Nielsen; Anders H Lund
Journal:  Mol Cell       Date:  2008-05-23       Impact factor: 17.970

9.  Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.

Authors:  Kazuo Motoyama; Hiroshi Inoue; Yoshito Nakamura; Hiroyuki Uetake; Kenichi Sugihara; Masaki Mori
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

10.  Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer.

Authors:  Young-Kook Kim; Jieun Yu; Tae Su Han; Seong-Yeon Park; Bumjin Namkoong; Dong Hyuk Kim; Keun Hur; Moon-Won Yoo; Hyuk-Joon Lee; Han-Kwang Yang; V Narry Kim
Journal:  Nucleic Acids Res       Date:  2009-01-19       Impact factor: 16.971

View more
  51 in total

1.  Novel circular RNA circNF1 acts as a molecular sponge, promoting gastric cancer by absorbing miR-16.

Authors:  Zhe Wang; Ke Ma; Steffie Pitts; Yulan Cheng; Xi Liu; Xiquan Ke; Samuel Kovaka; Hassan Ashktorab; Duane T Smoot; Michael Schatz; Zhirong Wang; Stephen J Meltzer
Journal:  Endocr Relat Cancer       Date:  2019-03       Impact factor: 5.678

2.  Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer.

Authors:  Zhaofeng Chen; Xiaoguang Liu; Zenan Hu; Yuping Wang; Min Liu; Xiaojun Liu; Hailong Li; Rui Ji; Qinhong Guo; Yongning Zhou
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

3.  [Role of miRNA-340 in modulating gastric cancer cell proliferation and bioinformatic analysis].

Authors:  Jian Wang; Wenjing Chen; Huijuan Lin; Jiangyu Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

Review 4.  MicroRNA and signaling pathways in gastric cancer.

Authors:  Z Zhang; Z Li; Y Li; A Zang
Journal:  Cancer Gene Ther       Date:  2014-07-25       Impact factor: 5.987

Review 5.  Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Authors:  Wenshan Lv; Fan Fan; Yangang Wang; Ezekiel Gonzalez-Fernandez; Chen Wang; Lili Yang; George W Booz; Richard J Roman
Journal:  Physiol Genomics       Date:  2017-11-10       Impact factor: 3.107

6.  Expression levels of microRNA-192 and -215 in gastric carcinoma.

Authors:  Yeunpo Chiang; Xin Zhou; Zhenning Wang; Yongxi Song; Zhuangkai Liu; Fang Zhao; Jinliang Zhu; Huimian Xu
Journal:  Pathol Oncol Res       Date:  2011-12-29       Impact factor: 3.201

7.  Soft-shelled turtle peptide modulates microRNA profile in human gastric cancer AGS cells.

Authors:  Yi-Chen Wu; Xiang Liu; Jiu-Li Wang; Xiang-Liu Chen; Lan Lei; Jing Han; You-Shui Jiang; Zhi-Qiang Ling
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

8.  MiR-215/192 participates in gastric cancer progression.

Authors:  Y J Xu; Y Fan
Journal:  Clin Transl Oncol       Date:  2014-07-01       Impact factor: 3.405

9.  miRNA-Based Therapeutic Strategies.

Authors:  Masaharu Ishida; Florin M Selaru
Journal:  Curr Anesthesiol Rep       Date:  2012-12-24

10.  microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer.

Authors:  Yeunpo Chiang; Yongxi Song; Zhenning Wang; Zhuangkai Liu; Peng Gao; Jiwang Liang; Jinliang Zhu; Chengzhong Xing; Huimian Xu
Journal:  Exp Ther Med       Date:  2011-12-28       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.